1,041 material Form 8-K filings that 824 companies we cover made with the SEC in November 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Powell Industries reported fourth-quarter fiscal 2025 revenue of $298 million, up 8%, and diluted earnings of $4.22 per share, up 12% from a year earlier. For the full fiscal year ended September 30, 2025, revenue rose 9% to $1.1 billion and diluted EPS rose 21% to $14.86. The company gave no numeric fiscal 2026 guidance, saying only that it expects another year of solid financial results.
Q4 fiscal 2025 net income was $51.4 million, or $4.22 per diluted share, versus $3.77 a year earlier.
Backlog was $1.4 billion as of September 30, 2025, up 3% from a year earlier but down 2% from June 30, 2025.
Q4 new orders were $271 million, up 1% from the prior year but down from $362 million in the third quarter of fiscal 2025.
Full-year net income was $180.7 million, or $14.86 per diluted share, up 21% from $149.8 million in fiscal 2024.
Medtronic reported second quarter fiscal 2026 results for the period ended October 24, 2025, with revenue of $8.961 billion and GAAP diluted EPS of $1.07, both up year over year. The company also raised its fiscal 2026 organic revenue growth and adjusted EPS guidance, which matters to shareholders because it signals higher expected earnings for the full year.
Revenue of $8.961 billion rose 6.6% as reported and 5.5% organic; Cardiac Ablation Solutions revenue increased 71%.
GAAP diluted EPS was $1.07, up 8%; non-GAAP diluted EPS was $1.36, also up 8%.
FY26 organic revenue growth guidance raised to approximately 5.5% from approximately 5.0%.
FY26 diluted non-GAAP EPS guidance set at $5.62 to $5.66, versus the prior $5.60 to $5.66, including a potential tariff impact of approximately $185 million.
NETSTREIT Corp. raised the low end of its full year 2025 AFFO per share guidance to a range of $1.30 to $1.31 per diluted share, according to a press release dated November 18, 2025. The company said it kept its 2025 net investment activity guidance of $350.0 million to $400.0 million and its cash G&A guidance of $15.0 million to $15.5 million, so the change applies to the bottom of the AFFO range only. For shareholders, the filing points to a higher expected floor for AFFO per share in 2025.
Full year 2025 AFFO per share guidance: low end raised to a range of $1.30 to $1.31 per diluted share
Net investment activity guidance maintained at $350.0 million to $400.0 million
Cash G&A guidance maintained at $15.0 million to $15.5 million, excluding transaction costs and severance payments
AFFO guidance continues to include $0.015 to $0.025 per share of estimated dilution from outstanding forward equity
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.